Drug Trial Radar · NCT03075267
Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects
Last checked: Nov 20, 2026Latest source record: Jan 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
96
Actual
Start
Apr 17, 2017
Primary completion
Sep 5, 2017
Study completion Sep 5, 2017
Sponsor
- Lead sponsor
- Pearl Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to assess the pharmacokinetics and safety of two doses of PT010 and a single dose of PT003 in healthy Chinese adult subjects
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
PT010 (BGF MDI) 320/14.4/9.6 µgDrug
A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
PT010 (BGF MDI) 160/14.4/9.6 µgDrug
A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
PT003 (GFF MDI) 14.4/9.6 µgDrug
A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Maximum Plasma Concentration (Cmax) - BudesonideTime frame: Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Maximum Plasma Concentration (Cmax) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Maximum Plasma Concentration (Cmax) - GlycopyrroniumTime frame: Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Maximum Plasma Concentration (Cmax) - FormoterolTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Maximum Plasma Concentration (Cmax) - FormoterolTime frame: Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - BudesonideTime frame: Day 8
- Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - GlycopyrroniumTime frame: Day 1
- Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - GlycopyrroniumTime frame: Day 8
- Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - FormoterolTime frame: Day 1
- Area Under the Plasma Concentration-time Curve From 0-12 Hours (AUC 0-12) - FormoterolTime frame: Day 8
- Time to Maximum Plasma Concentration (Tmax) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Time to Maximum Plasma Concentration (Tmax) - BudesonideTime frame: Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Time to Maximum Plasma Concentration (Tmax) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Time to Maximum Plasma Concentration (Tmax) - GlycopyrroniumTime frame: Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Time to Maximum Plasma Concentration (Tmax) - FormoterolTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Time to Maximum Plasma Concentration (Tmax) - FormoterolTime frame: Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - BudesonideTime frame: Day 1
- Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - GlycopyrroniumTime frame: Day 1
- Area Under the Plasma Concentration-time Curve From 0 to the Time of the Last Measurable Plasma Concentration (AUC 0-t) - FormoterolTime frame: Day 1
- Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - BudesonideTime frame: Day 1
- Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - GlycopyrroniumTime frame: Day 1
- Area Under the Plasma Concentration-time Curve From 0 Extrapolated to Infinity (AUC 0-∞) - FormoterolTime frame: Day 1
- Elimination Half-life (t½) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Elimination Half-life (t½) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Elimination Half-life (t½) - FormoterolTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Apparent Total Body Clearance (CL/F) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Apparent Total Body Clearance (CL/F) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Apparent Total Body Clearance (CL/F) - FormoterolTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Apparent Volume of Distribution (Vd/F) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Apparent Volume of Distribution (Vd/F) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Apparent Volume of Distribution (Vd/F) - FormoterolTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Terminal Elimination Rate Constant (λz) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Terminal Elimination Rate Constant (λz) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Terminal Elimination Rate Constant (λz) - FormoterolTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Accumulation Ratio for Cmax (RAC [Cmax]) - BudesonideTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose and Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Accumulation Ratio for Cmax (RAC [Cmax]) - GlycopyrroniumTime frame: Day 1 Pre-dose and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose and Day 8 Pre-dose -60, and 2, 6, 20, 40 min, 1, 2, 4, 8, 10, 12 and 24 h post-dose
- Accumulation Ratio for Cmax (RAC [Cmax]) - FormoterolTime frame: Day 1 and Day 8
- Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - BudesonideTime frame: Day 1 and Day 8
- Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - GlycopyrroniumTime frame: Day 1 and Day 8
- Accumulation Ratio for AUC 0-12 (RAC [AUC 0-12]) - FormoterolTime frame: Day 1 and Day 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.